Multiple Sclerosis :: Betaferon delays disability progession after multiple sclerosis attack
Patients treated with Betaferon? (interferon beta-1b) shortly after their first clinical MS event or ?attack? showed a 40 percent lower risk of developing confirmed disability when compared to patients in whom treatment was delayed. The results ? which were fast-tracked and published in The Lancet today ? provide the first controlled evidence that delaying Betaferon? treatment has an effect on later accumulation of disability. No other MS therapy has demonstrated this effect in this early patient population.